Manuel O. Méndez joined Quotient (NASDAQ:QTNT) as the company’s Chief Executive Officer in April 2021.
He brings over 30 years of experience in the diagnostics and life science markets. Mr. Méndez joins Quotient from Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services where he served as the Senior Vice President and Chief Commercial Officer. He played a key role in accelerating growth and supporting the COVID-19 efforts. Before joining Quest, he was living in Germany and served as SVP and Head of Global Commercial Operations and a member of QIAGEN N.V. Executive Committee, a worldwide provider of Sample to Insight solutions for molecular testing. Manuel has held a variety of senior leadership roles with Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies, and bioMerieux – living in the United States, Europe, Asia, and Latin America.
An American citizen, Mr. Méndez received an MBA from Northwestern University's Kellogg School of Management and a bachelor's degree in biomedical engineering from Boston University.
Peter Buhler joined Quotient (NASDAQ:QTNT) as the company’s Chief Financial Officer in February 2020. Mr Buhler has more than 20 years of experience in the strategic and financial leadership of life science and technology businesses in both the public and private sectors, more recently with Zaluvida AG, where he served as Group Chief Financial Officer.
In addition, Mr Buhler served as Group Chief Financial Officer of Greer Plc, a global leader in allergy immunotherapy headquartered in London.
While there, Mr Buhler led a complex merger project to combine a French and a US Group through the creation of a UK holding. Previously, he served as Head of Finance, Commercial Europe at Merck Serono SA and Finance Director EMEA at Logitech SA.
He is a Swiss Certified Accountant and an Executive MBA from the Swiss Business School in Zurich.
Jeremy Stackawitz joined Quotient (NASDAQ:QTNT) 10 years ago, overseeing the company through a period of sustained rapid growth. He led Quotient’s entry into the US market, where the company now serves over 1,000 customers and has successfully obtained over 60 FDA product approvals. He currently serves as President of Commercial and the Reagent Business.
He brings over 20 years of experience in healthcare, including diagnostics, pharmaceuticals and biotechnology. His past experiences include serving in various business development, general management and commercial roles for Johnson & Johnson, which included Commercial Director of Immunohematology for Ortho Clinical Diagnostics.
Previously he worked at Purdue Pharma running various Market Research and Commercial groups, and served as a Strategy Consultant to the healthcare industry with Monitor and McKinsey & Co consultancies.
Mr Stackawitz holds a BA in Chemistry from Dartmouth College and an MBA in Healthcare Management from The Wharton School, University of Pennsylvania.
Edward Farrell joined Quotient (NASDAQ:QTNT) in February 2013 and serves as President of R&D and Manufacturing, overseeing the product development and manufacturing of MosaiQ™ in Switzerland and Scotland.
Mr Farrell has over 20 years of engineering, manufacturing and R&D experience in medical diagnostics in various roles including several senior positions.
While with Siemens Healthcare Diagnostics, Mr Farrell served as Managing Director and Vice President with responsibility for R&D and manufacturing, for a point-of-care diagnostic instruments and consumables facility, and subsequently, for a high-volume immunoassay reagent plant in the United Kingdom. Prior experiences at Siemens include, working in the United States as Director for a Distribution, Service and Repair site, and as a Senior Manufacturing Manager in a large diagnostic instrument manufacturing plant in Ireland. Previously Mr Farrell worked at Ingersoll Rand as a Production Manager, as Intel Manufacturing Engineer and Supervisor.
Mr Farrell received a BE (Mechanical) and a Masters in Engineering Science from University College Dublin.